Journal
MULTIPLE SCLEROSIS AND RELATED DISORDERS
Volume 42, Issue -, Pages -Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.msard.2020.102108
Keywords
Myelin oligodendrocyte glycoprotein; Demyelination; Multiple sclerosis; Immunotherapy; Alemtuzumab; Disease control
Categories
Ask authors/readers for more resources
Immunoglobulin G (IgG) antibodies against myelin oligodendrocyte glycoprotein in serum denote an emerging autoimmune disorder of the central nervous system. Treatment trials have not been performed so far and anecdotal reports suggest that immunotherapies approved for multiple sclerosis (MS) may not be effective. We report favorable disease control with alemtuzumab, a CD52 depleting antibody approved for active MS, in a 34-year-old woman with the rarer condition of MOG-IgG disease with MS-phenotype. MOG-IgG in serum persisted over the entire observation period of almost five years. This case emphasizes that treatment responses may be distinct for different phenotypes of MOG-IgG associated disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available